Literature DB >> 21314128

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Ian R Hardcastle1, Junfeng Liu, Eric Valeur, Anna Watson, Shafiq U Ahmed, Timothy J Blackburn, Karim Bennaceur, William Clegg, Catherine Drummond, Jane A Endicott, Bernard T Golding, Roger J Griffin, Jan Gruber, Karen Haggerty, Ross W Harrington, Claire Hutton, Stuart Kemp, Xiaohong Lu, James M McDonnell, David R Newell, Martin E M Noble, Sara L Payne, Charlotte H Revill, Christiane Riedinger, Qing Xu, John Lunec.   

Abstract

Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors. The isoindolinone scaffold has proved to be versatile for the discovery of MDM2-p53 antagonists. Optimization of previously reported inhibitors, for example, NU8231 (7) and NU8165 (49), was guided by MDM2 NMR titrations, which indicated key areas of the binding interaction to be explored. Variation of the 2-N-benzyl and 3-alkoxy substituents resulted in the identification of 3-(4-chlorophenyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-nitrobenzyl)isoindolin-1-one (74) as a potent MDM2-p53 inhibitor (IC(50) = 0.23 ± 0.01 μM). Resolution of the enantiomers of 74 showed that potent MDM2-p53 activity primarily resided with the (+)-R-enantiomer (74a; IC(50) = 0.17 ± 0.02 μM). The cellular activity of key compounds has been examined in cell lines with defined p53 and MDM2 status. Compound 74a activates p53, MDM2, and p21 transcription in MDM2 amplified cells and shows moderate selectivity for wild-type p53 cell lines in growth inhibition assays.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314128     DOI: 10.1021/jm1011929

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

Review 2.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

3.  Antitumor evaluation and 3D-QSAR studies of a new series of the spiropyrroloquinoline isoindolinone/aza-isoindolinone derivatives by comparative molecular field analysis (CoMFA).

Authors:  Masoud Sadeghzadeh; Maryam Salahinejad; Nahid Zarezadeh; Mehdi Ghandi; Maryam Keshavarz Baghery
Journal:  Mol Divers       Date:  2017-08-23       Impact factor: 2.943

Review 4.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Tandem C(sp3)-H Arylation/Oxidation and Arylation/Allylic Substitution of Isoindolinones.

Authors:  Jacqueline Jiménez; Byeong-Seon Kim; Patrick J Walsh
Journal:  Adv Synth Catal       Date:  2016-08-02       Impact factor: 5.837

Review 6.  Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Authors:  Alexander H Stegh
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

Review 7.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

Review 8.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 9.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 10.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.